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Summary 
The molecular species of gastrin in the circulation and in tumor extracts were 
studied in two groups of patients: (1) with benign gastrinoma and (2) with gastrinoma 
with liver metastases. Radioimmunoassays (RIAs) and immunoaffinity chromato- 
graphy for the amino (NH2)- and amidated COOH-terminus of gastrin-17 (antiserum 
G17) and the NH2-terminus of gastrin-34 (antiserum G34) were employed. In both 
benign and metastatic tumors the molecular forms of gastrin in boiling water extracts 
measured by the gastrin-17 NH2- and COOH-terminal assays were similar. In ad- 
dition to a molecular component resembling the amidated gastrin-17, there were also 
significant amounts of larger molecular weight (mol. wt.) forms. The larger mol. wt. 
forms absorbed by the NH2-terminus of G17 antiserum corresponded to the 
COOH-terminus-extended forms of gastrip- 17. Furthermore, larger mol. wt. gastrins 
immunopurified by antiserum to the NH2-terminus of gastrin-34 corresponded to 
gastrin-34 extended molecules. Sera of patients with liver metastases had higher con- 
centrations of the NH2-terminal of gastrin-17 whereas sera of patients with benign 
gastrinoma contained predominantly gastrins detected by the COOH-terminal assay. 
These results suggest that: (a) there are differences in the molecular pattern of gastrin 
in the circulation of patients with benign and metastatic gastrinomas; (b) gastrins 
which are fully processed with carboxy-terminal amidation predominate in the cir- 
culation of patients with benign gastrinoma; and (c) gastrins containing the gastrin-17 
and COOH-terminally extended gastrin-17 and gastrin-34 precursor molecules occur 
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in high concentration in the circulation of gastrinoma patients with metastases to the 
liver. 
Gastrin; Gastrinoma; Radioimmunoassay; Liver metastase 
Introduction 
Gastrin in gastrinoma syndrome is heterogenous. It is found as peptides of variable 
amino acid chain length. The known gastrin peptides are gastrin-34, gastrin-17, gas- 
trin-14, Component I, the NH2-terminus tridecapeptide 1-13 gastrin-17 and a non° 
apeptide extension at the COOH-terminus of gastrin [1--6]. Gastrin-34, gastrin-17 
and gastrin-14 have a common amidated carboxy-terminus. The nonapeptide-ex- 
tended forms of gastrin contain a Phe-Gly linkage instead of Phe-NH2 at the 
COOH-terminus. Since previous studies used carboxy-terminus antisera [2], and car- 
boxy-terminus immunoaffinity absorption [3], this extension of the gastrin molecule 
may have precluded recognition by antisera to the amidated gastrins and dictates a 
need to utilize radioimmunoassays (RIAs) capable of recognition of these variants 
if they are to be quantitated in tissues and biologic fluids. 
We have previously described the development of region-specific RIAs for gastrin 
[7] and their utilization in distinction between benign and metastatic gastrinoma [8]. 
In the present studies we have characterized the molecular forms of gastrin in extracts 
of tumor and in the circulation of patients with gastrinoma. The results suggest that 
even though tumor extracts contain multiple molecular forms of gastrin, amidated 
gastrin-34 is the major form in the circulation of patients with benign tumors, whereas 
gastrin-17 and the COOH-terminally extended gastrins predominate in the serum of 
patients with gastrinoma and liver metastases. 
Materials and Methods 
Peptides. Pure natural gastrin-34, and 1-13 gastrin-17 were gifts from Prof. R.A. 
Gregory and Hilda J. Tracy (Liverpool). Synthetic gastrin-17, 1-12 gastrin-17 and 
1-16 [TyrlT]gastrin-34 were gifts from ImmunoNuclear Corp, StiUwater, MN. Car- 
boxy-terminal-extended fragments (EGI0) were a gift from K.L. Agarwal, Chicago, 
IL. Gastrin-34 and 1-20 gastrin-34 (Kenner-Harris sequence) were purchased from 
Fluka Chemical, Hauppauge, NY. Gastrin-16 and gastrin-10 were purchased from 
GRB, Atlantic Beach, NY. 
Patients. The clinical details of the 22 patients studied have been described pre- 
viously [9-11]. All patients had surgically proven gastrinomas and the blood samples 
were taken prior to surgery. Of the 22 patients studied, 14 had benign gastrinomas 
and 8 had metastases to the liver. 
Tumor extraction. The tumors obtained at operation were frozen immediately. The 
frozen tumors were weighed, cut into small pieces and then boiled in 10 ml of water 
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[1-5] (pH 7.0) for 10 min, homogenized in a Pyrex tissue grinder and centrifuged at 
2000 rpm for 10 min. The supernatant was decanted and frozen at -20"C until ready 
for analysis. 
Gel chromatography. The samples were fractionated at 4°C on columns of Sephadex 
G50 (superfine, 100 x 1 cm), equilibrated and eluted with 0.02 M Tris-HC1 buffer, 
pH 8.0, containing 0.2 g/liter sodium azide and 0.001% bovine serum albumin. The 
columns were calibrated with gastrin-34, gastrin-17, gastrin-14, gastrin-13, 1-16 
[Tyr 1V]gastrin_34, 1-13 gastrin- 17 and 1-12 gastrin- 17. With each chromatographic 
analysis, very small amounts of purified albumin were added to mark the void volume 
and Na12SI for the salt peak. The protein peak in the column eluates was detected 
by light absorption at 280 nm. The elution profiles are described in terms of percent 
of the elution volume between the protein peak (0%) and the salt peak (100%). 
Values are given as a % or as a fraction of the total volume (Kav). The columns were 
eluted at a flow rate of 4.0 ml/min and fractions of 0.5-1 ml were collected for the 
assays unless otherwise specified. Recoveries (in percent) of gastrins were: gastrin-34, 
70 + 3; gastrin-17, 84 4- 3; gastrin-14, 68 4- 2; 1-12 gastrin-17, 89 4- 1; 1-13 
gastrin-17, 81 4- 1; and 1-16 [Tyr17]gastrin-34, 87 ± 3, means + S.E.M. 
Antisera. Four antisera were used. They recognized (i) the amidated COOH-ter- 
minus of gastrin-17 and gastrin-34 (G); (ii) NH2-terminus of gastrin-17 (MG2); (iii) 
NH2-terminus of gastrin-34 (R34); and (iv) COOH-terminally extended gastrins 
(EG10). The antiserum to the COOH-terminal-extended gastrin (EG10) reacted with 
amidated and non-amidated gastrins equally well. Further, since the gastrin-30-39 
sequence is identical in rat preprocholecystokinin, the antiserum generated using the 
COOH-terminally extended gastrin (EG10) was used only for confirmation of the 
presence of COOH-terminal-extended fragments. The antisera raised against the 
amidated COOH-terminus of gastrin-16 (G), NH2-terminus of 1-13 gastrin-17 
(MG2) and NH2-terminus of gastrin-34 (R34) proved to be useful in the present 
studies. 
RIA. The methods for the RIAs using antisera G, MG2 and R34 have been re- 
ported in detail [7,8]. Fig. 1 gives the sequence of gastrin and the recognition sites of 
the 3 antisera, G, MG2 and R34. Antiserum raised against the COOH-terminal- 
extended gastrin EG10 reacted equally with EG10, gastrin-14, gastrin-17 and gas- 
trin-34. However, it did not react with 1-13 gastrin-17. Labeled gastrin-17 was used 
as a tracer. The use of labeled EG10 peptide as tracer did not alter the specificity. 
This suggests that EG10 antiserum needs the 31-34 aminoacid residues of the gas- 
trin-34 sequence for the reaction. The IDso was 68 pM. The intra-assay coefficient 
of variation was 13% at 25 pM and 6% at 250 pM of G17. 
lmmunoabsorption. In order to purify and establish the identity of the individual 
peaks measured by the 3 RIAs in gel chromatography eluates, immunoaffinity chro- 
matography using antisera G, MG2 and R34 was used to isolate various gastrin 
species. The immunoglobulins from 5 ml of these antisera were precipitated by the 
addition of 5 ml of saturated ammonium and coupled to 300 #g of CNBr activated 
Sepharose 4B according to the manufacturer's instruction (Pharmacia, Uppsala, Swe- 
den). Three separate immunoabsorbent columns (10 x 1 cm) were prepared. The 
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Fig. 1. The aminoacid sequence of human gastrin-34 is shown in (A) and that of COOH-terminally 
extended gastrin-34 as deduced from gene studies is shown in (B). Braces indicate the sequences of gastrin 
which the antisera recognize. Boxes indicate the bonds cleaved by trypsin. 
After an initial wash with 40 ml of 0.02 M Tris HCI (pH 8.0), gastrins bound to the 
column were desorbed by elution with 1 M acetic acid. The eluates were lyophilized 
and reconsituted in the assay buffer. Table I shows the binding capacity of the im- 
munoaffinity columns for gastrin-34, gastrin- 17, gastrin- 14, 1-13 gastrin- 17, and 1- 
16 [Tyr 17]gastrin-34. As shown, the immunoaffinity column using antiserum G bound 
only peptides containing the amidated carboxy terminus of gastrin; antiserum MG2 
bound only the peptides containing the NH2-terminus of gastrin-17; and antiserum 
R34 bound only the peptides containing the NH2-terminus of gastrin-34. 
TABLE I 
Abso'rption (%) of 10 nM of various gastrin molecular forms of gastrin by 3 immunoattinity columns 
Immunoattinity columns 
G MG2 R34 
Peptide 
1-16[Tyr 1 ~]gastrin-34 0% 0% 95% 
Gastrin-34 100% 1% 100% 
Gastrin- 17 100% 97% 0% 
Gastrin-14 100% 0% 0% 
1-13 Gastrin-I 7 2% 95% 0% 
The gastrin content of washings and desorbed material was measured by RIA's using appropriate antisera. 
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Results 
Gastrins in tumor extracts 
Chromatography on Sephadex G50 (superfine) of the tumor extracts resolved the 
immunoreactive fractions measured by antiserum G (which recognizes the amidated 
COOH-terminus of gastrin) into 5 peaks (Fig. 2). These peaks eluted at Kay values 
of 0.0, 0.25, 0.40, 0.55 and 0.75, that correspond to the known gastrin molecules big 
big gastrin (BBG), Component I, gastrin-34, gastrin-17, and gastrin-14 [3]. An ad- 
ditional peak at a Kay of 0.85 was also identified in 3 tumors [12]. The Sephadex G50 
profile of G-immunoaffinity-purified material was similar to that of the extracted 
tumor as measured by antiserum G (Fig. 2). The differences between the profiles 
shown in Fig. 2 are due to marked differences in the gastrin-14 content in the tumors 
of patients 1-3. Antiserum MG2 identified only a peak corresponding to gastrin-17, 
whereas R34 identified a peak resembling gastrin-34 in the G-immunoaffinity-purified 
eluates (data not shown). These data indicated that all 5 identified species contain 
the COOH-terminus of gastrin. Furthermore, the position of individual peaks re- 
mained unchanged on Sephadex G50 column chromatography in 8 M urea, indicat- 
ing that the large molecular weight species were not polymers held together by non- 
covalent forces. The incubation of BBG, Component I and gastrin-34 with trypsin 
displaced the immunoreactivity to the elution position of synthetic G 17 as measured 
by antiserum G, confirming that all the molecular species contained the COOH- 
terminus of gastrin- 17. 
Studies of the Sephadex G50 elution profile of the tumor extracts using antiserum 
MG2 resolved the immunoreactive fractions into 7 peaks (Fig. 3). The peaks eluted 
at K,v values of 0.05, 0.18, 0.25, 0.42 (all 4 peaks (I-IV) resembled those identified 
by Rehfeld [5]), 0.49 (resembling pure 1-13 gastrin-17), 0.53 (peak V) and 0.55 (re- 
sembling synthetic gastrin-17. The Sephadex G50 profile of MG2-immunoaffinity- 
desorbed material was similar to that of the tumor extracts as measured by antiserum 
MG2 (Fig. 3). Antiserum G detected only a peak resembling gastrin-17 at a K,~ of 
0.55 whereas antiserum R34 did not recognize any of the peaks detected by MG2 in 
these MG2-immunoaffinity-purified eluates. This confirmed that all the peaks mea- 
sured contained the NHe-terminus of gastrin-17 and only the peak resembling gas- 
trin-17 at Kay of 0.55 had the amidated COOH-terminus of gastrin-17. 
Further studies of MG2-immunoaffinity-purified eluates using an antiserum that 
reacts with carboxy-terminally extended gastrin and amidated COOH-terminus of 
gastrin measured peaks I-V, and one resembling gastrin-17 but not the one resem- 
bling 1-13 gastrin-17. This suggested that peaks I-V, which are not measured by 
antiserum G, contain the NH2-terminus of gastrin-17 and are extended at the car- 
boxy-terminus of gastrin-17. Furthermore, in 8 M urea, the position of individual 
peaks on the Sephadex G50 column chromatography remained unchanged as mea- 
sured by antiserum MG2. Separate incubation of peaks I-IV with trypsin displaced 
the immunoreactivity to the position corresponding to peak V as measured by anti- 
serum MG2. None of the displaced peaks were measurable by antisera G or R34. 
Peak V and peaks resembling 1-13 gastrin-17 and gastrin-17 were not displaced by 
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Fig. 2 (left). Chromatography of Sephadex G50 (superfine) of tumor extracts. Gastrin immunoreactivity 
as measured by antiserum G using synthetic gastrin-17 (17) as standard is shown on the ordinate. The 
hatched bars indicate the ranges of concentration observed in the tumors examined. On the abscissa, 
percentage of elution volume between the protein peak (void volume 0%) and Nal 2 si peak (I 00% volume) 
is given. Elution volume of natural gastrin-34 (34) and synthetic gastrin-17 (17), gastrin-14 (14) and gas- 
trin-4 (4) are given. Elution profile of boiling tumor extract (top) and G-immunoatiinity-desorbed tumor 
(No. 3) extract (bottom). 
Fig. 3 (right). Chromatography of tumor extracts on Sephadex G50. For details see Fig. 2. Elution volume 
of pure 1-13 gastrin-17 (1-13 (17)) and synthetic gastrin-17 (17) measured by antiserum MG2 are given. 
Elution profile of boiling-water tumor extract measured by antiserum MG2 (upper panel) and MG2- 
immunoaflinity-desorbed tumor (No. 2) extracts measured by antiserum MG2 ( - )  and G (dark area; 
bottom panel) are given. The hatched bar in the upper panel indicates range of concentrations between 
patients in tumors examined. Note: the peak resembling gastrin-17 was recognized by antisera G and 
MG2. 
minus o f  gastrin-17 and are extended at the COOH-terminus o f  gastrin-17. 
Table II gives the concentration of  immunoreactive gastrin peaks measured by 
antisera G and M G 2  in the gastrinomas. Individual peak concentrations varied con- 
siderably in benign gastrinoma. However,  the total COOH-terminus immunoreactiv- 
ity was lower than total NH2-terminus immunoreactivity in cases o f  gastrinoma with 
liver metastases. Furthermore, one of  the tumors examined (No.  15) had peaks mea- 
sured by antiserum MG2,  i.e., containing the NH2-terminus o f  gastrin-17, and ami- 
dated gastrin-17, but had no gastrin-34 or Component  I as measured by antiserum 
G. N o  attempts were made to quantify peak V due to the low concentration in benign 
gastrinoma and extremely high concentrations in patients with liver metastases. 
Gastrins in the circulation 
Chromatography on Sephadex G50 columns of  serum from patients with benign 
gastrinoma and gastrinoma with liver metastases resolved the immunoreactivity into 
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Fig. 4. Chromatography of sera on Sephadex G50. For details see Figs. 2 and 3. Elution profile of sera 
from patients with spor/ldic gastrinoma (upper panels) and liver metastases (bottom panels) are given. 
The left panels (A1, B1) were measured by antiserum G and right panels (A2, B2) by antiserum MG2. The 
hatched bar indicates range of concentrations between patients in sera examined. 
by antiserum G (Fig. 4A1, B0. However, antiserum MG2 measured peaks resembling 
gastrin-17 and 1-13 gastrin-17 in gastrinoma (Fig. 4A2) and various amounts of all 
7 peaks in gastrinoma with liver metastases (Fig. 4B2). 
The total immunoreactivity containing the COOH-terminus of gastrin as measured 
by antiserum G was higher than NH2-terminus of gastrin-17 immunoreactivity as 
measured by antiserum MG2 in the serum of patients with benign gastrinoma (Table 
III). In addition, the relative concentration of gastrin-17 was less than 20% of total 
COOH-terminus immunoreactivity in all patients with benign gastrinoma as mea- 
sured by antiserum G (not shown). 
In contrast, total NH2-terminus of gastrin-17 immunoreactivity measured by anti- 
serum MG2 was higher than COOH-terminus gastrin as measured by antiserum G 
in 7 out of 8 patients with liver metastases (Table III). Furthermore, the relative 
concentration of gastrin-17 was higher than 20% of total COOH-terminus immu- 
noreactivity in patients with liver metastases as measured by antiserum G (data not 
shown). 
COOH-terminally extended big gastrin 
Chromatography on Sephadex G50 of the 3 tumor extracts resolved the immu- 
noreactivity into 8 fractions eluting at Kav of 0.02, 0.08, 0.2, 0.35 (peaks A-D), 0.4 
(resembling pure G34), 0.5 (resembling NH2,terminus tryptic peptide of G34 (peak 
E), 0.68 (peak F) and 1.00 (peak G) as measured by antiserum R34 (Fig. 5). The 3 
later peaks have been identified in human plasma [13]. The Sephadex G50 profile of 
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Fig. 5. Gel chromatography of tumor extracts on Sephadex G50. For column details see Fig. 2. Elution 
volume of pure gastrin-34 and NH2-terminal heptadecapeptide of gastrin-34 (NT(34)) measured by anti- 
serum R34 are given. Elution profile of boiling-water tumor extracts as measured by antiserum R34 (upper 
panel) and R34-immunoaffinity-desorbed tumor (No. 6) extracts measured by antisera R34 ( - )  and G 
(dark area; bottom panel) are given. The hatched bar in upper panel indicates range of concentration 
between patients in tumor examined. 
measured by antiserum R34 (Fig. 5). Only the peak eluting at a Kay of 0.4 was 
measured by antiserum G, whereas antiserum MG2 did not recognize any peak in 
R34-immunoaffinity-purified eluates (data not shown). These data indicate that the 
peaks measured contain the NH2-terminus of gastrin-34 and only the peak resem- 
bling gastrin-34 has the amidated COOH-terminus of gastrin. 
Further studies of R34-immunoaflinity-purified eluates using an antiserum that 
reacts with carboxy-terminally extended gastrin and the amidated COOH-terminus 
of gastrin recognized peaks A-D and one resembling gastrin-34. This suggests that 
peaks A-D, which are not measured by antiserum G, contain the NH2-terminus of 
gastrin-34 and are extended at the carboxy-terminus. Furthermore, incubation of 
pooled peaks (A-D) with trypsin displaced the immunoreactivity to the position of 
the NH2-terminus tryptic peptide of gastrin-34 at a Kay of 0.5 as measured by anti- 
serum R34. Antiserum G did not recognize any peaks in the eluates. In contrast, 
trypsin treatment of the peak eluting at a Ka~ of 0.4 (resembling pure gastrin-34) 
displaced the immunoreactivity to the position of the NH2-terminus tryptic peptide 
of gastrin-34 at a Kav of 0.5 as measured by antiserum R34 and to the position of 
gastrin-17 as measured by antiserum G. Peaks eluting at a K~ of 0.5, 0.68 and 1.00 
were not displaced by trypsin. This confirms that peaks A-D contain the NH2-ter- 
minus of gastrin-34 and are extended at the COOH-terminus of gastrin. 
Since the gastrin gene contains the sequence of both gastrin-17 and gastrin-34 and 
their extension, the reason for the finding of one less peak of carboxy-terminally 
extended gastrin-34 than gastrin-17 is not clear. However, this was attributed to poor 
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TABLE IV 
Immunoreactive gastrin concentration (nmol/g wet wt.) of individual peaks in tumor extracts estimated 
using antiserum R34. 
Patient A B C D Gastrin-34 E F G Total 
Benign 
1 0.20 1.70 1.10 3.90 6.60 0.22 0.22 
5 2.60 25.00 62.60 106.60 26.00 21.10 
Liver metastases 
15 





RIAs were performed using antiserum R34 for the amino-terminus ofgastrin-34 measurements. The results 
are expressed relative to gastrin-34 standard. Concentrations were estimated by integration of all eluates 
corresponding to the peak from chromatography on Sephadex G50 (Fig. 5). 
resolution on the Sephadex G50 columns. Attempts to resolve them further were not 
successful. No striking differences were observed in the individual peak concentra- 
tions in two benign sporadic and one gastrinoma tumor with liver metastases (Table 
IV). 
The chromatography of the 3 sera from patients with sporadic gastrinoma showed 
a major peak eluting at a Kay of 0.4 (resembling G34) along with the minor peaks 
eluting at Kay values of 0.5, 0.68 and 1.00 corresponding to fragments of gastrin-34 
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Fig. 6. Gel chromatography of sera on Sephadex G50. For details see Figs. 2, 5. Elution profile of sera 
from patients with sporadic gastrinoma (upper panel) and liver metastases (bottom panel), measured by 
antiserum R34 are given. The hatched bar indicates the range of concentrations in sera examined. Note: 
peak D was not observed in sporadic gastrinoma. 
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TABLE V 
Immunoreactive gastrin concentration (picomolarity) of  immunoreactive peaks in sera from 6 patients 
using antiserum R34 










225 25 10 10 270 
7000 80 16 24 7120 
470 10 50 10 540 
<1 
20 26 46 
24 74 98 
300 1000 1300 
RIAs were performed using antiserum R34 for the amino-terminus of  gastrin-34 measurements. The results 
are expressed relative to gastrin-34 standard. Concentrations were estimated by integration of  all eluates 
corresponding to the peak from chromatography on Sephadex G50 (Fig. 6). 
sponding to carboxy-terminally extended gastrin (described in tumor) at a K,v of 0.35 
and resembling pure gastrin-34 at K,v of 0.4. Additional experiments confirmed the 
identity of the peaks (Fig. 6, Table V). As noted earlier, gastrin-34 was not identified 
in patient No. 15 (Table V). 
Discussion 
The immunochemical studies using antisera directed at the different regions of the 
gastrin molecule, in combination with chromatography, indicate that gastrin present 
in the tumor extracts and serum from patients with the gastrinoma syndrome is 
heterogenous. Furthermore, the molecular species in serum differ from that in the 
tumor. The predominant molecular forms in the serum of patients with sporadic 
gastrinoma are the COOH-terminally amidated gastrin peptides whereas the sera of 
patients with liver metastases contained gastrin molecular forms that are extended 
at its COOH-terminus and gastrin-17. 
Even though efforts were made to study gastrin molecular heterogeneity in the 
gastrinoma syndrome using an antiserum directed at the COOH-terminus of gas- 
trin-17 [2,3] (Fig. 2) COOH-terminally extended peptides containing the Phe-Gly 
linkage are not recognized by the antisera used. Using a NH2-terminus of gastrin- 
17- and gastrin-34-directed antisera, molecules with a COOH-terminus extension 
could be identified. 
Previous studies in the gastrinoma syndrome have defined the presence of 1-13 
gastrin-17 [4] and 4 peaks corresponding to COOH-terminally extended gastrin-17 
[5] as measured by NH2-terminus-directed antisera. In addition to identifying peak 
V corresponding to COOH-terminally extended gastrin-17, the present study has also 
identified peaks corresponding to COOH-terminally extended gastrin-34 (Figs. 3,5,6). 
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Whether the larger molecular weight peaks measured by antisera MG2 and R34 
reflect extension beyond the nonapeptide sequence [6] (Fig. 1) is speculative. Noyes 
et al. [14] have shown that porcine gastrin mRNA has 620 nucleotides of which 
250-300 nucleotides were 3' to the coding region for gastrin-17, which could em- 
brance a greater-than-nonapeptide extension, although it is unlikely that the molecular 
species identified with COOH-terminal extension represent translation of the 3' end 
of the gastrin gene. The large forms probably comprise unprocessed products of 
nonapeptide-extended forms as shown by Sugano et al. [15], who measured different 
immunoreactive peaks in porcine antral extract using 3 antisera specific for the 
COOH-terminus of gastrin-17, its extension by Gly and Gly-Arg-Arg. The apparently 
high molecular weight may be due to altered elution of COOH-terminal-extended 
molecules on the Sephadex column. The failure of COOH-terminal antiserum to 
recognize COOH-terminally extended gastrin and the use of NH2-terminal antisera 
in the present study, and detailed classification of our patients may explain the dis- 
crepancy between this and earlier reports [2,3]. 
The distribution pattern of gastrin in the circulation of patients with sporadic 
gastrinoma differed from that in 7 patients with liver metastases. While the latter 
contained high concentrations of gastrin-17 NH2-terminal immunoreactivity, the 
gastrin COOH-terminal immunoreactivity predominated in the circulation of 
patients with benign gastrinoma (Table III). These data further verify our earlier 
finding of a high NH2:COOH ratio in patients with liver metastases [8,16]. The reason 
for this differential pattern is unknown, however, it may be due to the difference in 
the rate of processing of the gastrin molecule, particularly ~-amidation of Phe residue 
in position 34 of gastrin (Fig. 1) [17]. Since COOH-terminally extended gastrin-34 
has the same dibasic Arg-Arg sequence as COOH-terminally extended gastrin-17, the 
finding of COOH-terminally extended gastrin-34 and gastrin-17 in the serum of 
patients with liver metastases supports the hypothesis that metastatic tumors incom- 
pletely clear the extended precursors. The reason for finding high COOH-terminus 
gastrin in the serum of patient No. 17 is unknown. 
Johnson and Fabri [18] have reported that G17 accounts for more than 20% of 
the total gastrin in all patients with metastatic gastrinoma and less than 20% in 
patients with benign sporadic gastrinomas. Our studies using a COOH-terminus- 
directed antiserum support this finding. 
Carboxy-terminally extended gastrins (residues 18-43 and 1-43) and the gastrin- 
34 sequence contain gastrin-17. This raises the possibility that they are precursors of 
gastrin-17. However, the finding of amidated G I 7 in the circulation in the absence 
of gastrin-34 in tumor extracts and the circulation in patient No. 15 suggests that 
the COOH-terminally extended gastrin-17 may be the precursor of gastrin-17. Fur- 
thermore, the finding of both carboxy-terminally extended gastrin-34 and gastrin- 17 
in the same tumor (Figs. 3,5) suggests that these are the independent precursors of 
gastrin-17 and gastrin-34. This will have to be demonstrated more directly. 
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